These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 34633639)

  • 21. Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy.
    Ansaldi F; Pugh S; Amicizia D; Di Virgilio R; Trucchi C; Orsi A; Zollo A; Icardi G
    Pathogens; 2020 Jan; 9(2):. PubMed ID: 31979079
    [No Abstract]   [Full Text] [Related]  

  • 22. 20-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults.
    Shirley M
    Drugs; 2022 Jun; 82(9):989-999. PubMed ID: 35793027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Higher-valency pneumococcal conjugate vaccines in older adults, taking into account indirect effects from childhood vaccination: a cost-effectiveness study for the Netherlands.
    de Boer PT; van Werkhoven CH; van Hoek AJ; Knol MJ; Sanders EAM; Wallinga J; de Melker HE; Steens A
    BMC Med; 2024 Feb; 22(1):69. PubMed ID: 38360645
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis.
    Pugh S; Wasserman M; Moffatt M; Marques S; Reyes JM; Prieto VA; Reijnders D; Rozenbaum MH; Laine J; Åhman H; Farkouh R
    Infect Dis Ther; 2020 Jun; 9(2):305-324. PubMed ID: 32096144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands.
    Strutton DR; Farkouh RA; Earnshaw SR; Hwang S; Theidel U; Kontodimas S; Klok R; Papanicolaou S
    J Infect; 2012 Jan; 64(1):54-67. PubMed ID: 22085813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India.
    Ghia CJ; Horn EK; Rambhad G; Perdrizet J; Chitale R; Wasserman MD
    Infect Dis Ther; 2021 Dec; 10(4):2271-2288. PubMed ID: 34313958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece.
    Gourzoulidis G; Barmpouni M; Kossyvaki V; Vietri J; Tzanetakos C
    Front Public Health; 2023; 11():1229524. PubMed ID: 37841729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population.
    Lytle D; Grajales Beltrán AG; Perdrizet J; Ait Yahia N; Cane A; Yarnoff B; Chapman R
    Hum Vaccin Immunother; 2023 Aug; 19(2):2257426. PubMed ID: 37771288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants.
    Rozenbaum MH; Huang L; Perdrizet J; Cane A; Arguedas A; Hayford K; Tort MJ; Chapman R; Dillon-Murphy D; Snow V; Chilson E; Farkouh RA
    Vaccine; 2024 Jan; 42(3):573-582. PubMed ID: 38191278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The 20-valent pneumococcal conjugate vaccine (PCV20): expected added value.
    Janssens E; Flamaing J; Vandermeulen C; Peetermans WE; Desmet S; De Munter P
    Acta Clin Belg; 2023 Feb; 78(1):78-86. PubMed ID: 35171752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of PCV10, PCV13, PCV15, PCV20 and PPSV23 vaccine coverage of invasive Streptococcus pneumoniae isolate serotypes in Canada: the SAVE study, 2011-20.
    Schellenberg JJ; Adam HJ; Baxter MR; Karlowsky JA; Golden AR; Martin I; Demczuk W; Mulvey MR; Zhanel GG
    J Antimicrob Chemother; 2023 May; 78(Suppl 1):i37-i47. PubMed ID: 37130588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants.
    Perdrizet J; Horn EK; Nua W; Perez-Peralta J; Nailes J; Santos J; Ong-Lim A
    Infect Dis Ther; 2021 Dec; 10(4):2625-2642. PubMed ID: 34591259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outpatient visits and antibiotic use due to higher valency pneumococcal vaccine serotypes.
    King LM; Andrejko KL; Kabbani S; Tartof SY; Hicks LA; Cohen AL; Kobayashi M; Lewnard JA
    J Infect Dis; 2024 Mar; ():. PubMed ID: 38498565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the pediatric population in South Korea.
    Kang DW; June Choe Y; Lee JY; Suk IA; Kim YS; Kim HY; Byun BK; Park SK
    Vaccine; 2024 Jun; ():. PubMed ID: 38845302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Invasive Pneumococcal Disease Epidemiology and Serotype Replacement After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Ontario, Canada, 2007-2022.
    Grewal R; Hillier K; Deeks SL; Yeung AH; Wilson SE; Wijayasri S; Harris TM; Buchan SA
    Open Forum Infect Dis; 2024 Jun; 11(6):ofae275. PubMed ID: 38868312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong.
    Wu DB; Roberts C; Lee VW; Hong LW; Tan KK; Mak V; Lee KK
    Hum Vaccin Immunother; 2016; 12(2):403-16. PubMed ID: 26451658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pneumococcal serotype evolution in Western Europe.
    Tin Tin Htar M; Christopoulou D; Schmitt HJ
    BMC Infect Dis; 2015 Oct; 15():419. PubMed ID: 26468008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease Among Adults With HIV-United States, 2008-2018.
    Kobayashi M; Matanock A; Xing W; Adih WK; Li J; Gierke R; Almendares O; Reingold A; Alden N; Petit S; Farley MM; Harrison LH; Holtzman C; Baumbach J; Thomas A; Schaffner W; McGee L; Pilishvili T
    J Acquir Immune Defic Syndr; 2022 May; 90(1):6-14. PubMed ID: 35384920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants.
    Perdrizet J; Santana CFS; Senna T; Alexandre RF; Sini de Almeida R; Spinardi J; Wasserman M
    Hum Vaccin Immunother; 2021 Apr; 17(4):1162-1172. PubMed ID: 32966176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimating the population health and economic impacts of introducing a pneumococcal conjugate vaccine in Malaysia- an economic evaluation.
    Shafie AA; Ahmad N; Naidoo J; Foo CY; Wong C; Pugh S; Tan KK
    Hum Vaccin Immunother; 2020 Jul; 16(7):1719-1727. PubMed ID: 31951782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.